Srdan Verstovsek, MD, PhD | Authors


Improving Patient Outcomes With Ruxolitinib in Advanced Myelofibrosis

December 16, 2020

Srdan Verstovsek, MD, PhD, discusses how research and future clinical trials can better determine the benefit of ruxolitinib as treatment of patients with myelofibrosis, which is often measured in improvements in the quality of life and spleen reductions.

New Therapies in Development for Myelofibrosis

October 15, 2020

Building on the transformative impetus from the first FDA-approved JAK 1/2 inhibitor, ruxolitinib, in the clinical landscape of myeloproliferative neoplasms, we are entering a new era of multiple JAK inhibitors and other diverse classes of drugs in rapid clinical development.